middle.news
Immutep’s IMP761 Shows Strong Safety and Immune Control in Phase I Trial
8:32am on Thursday 19th of March, 2026 AEDT
•
Biotechnology
Read Story
Immutep’s IMP761 Shows Strong Safety and Immune Control in Phase I Trial
8:32am on Thursday 19th of March, 2026 AEDT
Key Points
Single ascending dose phase of IMP761 completed with no safety concerns
IMP761 shows durable inhibition of T-cell responses after one dose
Multiple ascending dose phase underway, expected to finish Q3 2026
Data to be presented at EULAR conference in June 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE